drug pricing

AstraZeneca says MFN policy changed its drug launch pricing

AstraZeneca disclosed on Monday that it has shifted its pricing approach for new drug launches in response to the Trump administration's most-favored-nation policy, as the company reported second-quarter earnings that beat profit expectations.

Eli Lilly says Trump pricing policy will delay obesity drug launches in Europe

Eli Lilly said on Tuesday that the Trump administration's most-favored-nation pricing policy will affect its plans to launch its weight-loss pill in Europe and Britain, with the rollout now expected in the second half of 2026 or early 2027. The…